8-K: Propanc Biopharma Secures $41,000 in Funding Through Convertible Promissory Note

Propanc Biopharma has entered into a securities purchase agreement, securing $41,000 in funding through the issuance of a convertible promissory note with a principal amount of $49,200.

Summary

• Propanc Biopharma has secured a $41,000 investment through a convertible promissory note with 1800 Diagonal Lending LLC.
• The note has a principal amount of $49,200, which includes an $8,200 original issue discount.
• A one-time interest charge of 15%, amounting to $7,380, is applied on the issue date.
• The total repayment amount is $56,580, payable in five installments between December 2024 and April 2025.
• The note matures on April 15, 2025.
• The note can be prepaid in full at any time without penalty.
• The investor has the option to convert the outstanding balance into common stock after an event of default.
• The conversion price is 65% of the lowest trading price in the 10 days prior to conversion, representing a 35% discount.
• The company is required to reserve four times the number of shares issuable upon full conversion of the note, initially 302,769,230 shares.
• The note includes various events of default, such as failure to pay, breach of covenants, and delisting of common stock.

Sentiment

Score: 4

Explanation: The document indicates a high-risk financing agreement with unfavorable terms for the company, including high interest rates and a significant conversion discount. While the funding is positive, the terms suggest a weak negotiating position for the company.

Positives

• The company has secured immediate funding of $41,000.
• The note can be prepaid at any time without penalty, providing flexibility.
• The conversion feature provides the investor with potential upside if the company's stock price increases.
• The company has a five-day grace period for each payment.

Negatives

• The note carries a high interest rate of 15% upfront and 22% on default.
• The company is obligated to make five large payments over a short period.
• The conversion price is based on a discount to the trading price, which could dilute existing shareholders.
• The note includes numerous events of default that could trigger immediate repayment.

Risks

• Failure to make timely payments will result in a 22% default interest rate.
• Breaching any of the covenants in the note or purchase agreement could trigger an event of default.
• The company's stock price could decline, making conversion less attractive for the investor.
• The company may face challenges in maintaining its stock listing on an exchange.
• The company's financial statements could be restated, triggering an event of default.

Future Outlook

The company intends to use the net proceeds from the note for general working capital purposes.

Management Comments

• The company intends to use the net proceeds therefrom for general working capital purposes.

Industry Context

This type of financing is common for small biotech companies seeking to fund operations and research. The terms of the note, including the high interest rate and conversion discount, reflect the risk associated with investing in early-stage biotech companies.

Comparison to Industry Standards

• The 15% upfront interest and 22% default interest are relatively high compared to traditional bank loans, but are not uncommon for bridge financing in the biotech sector.
• The 35% discount on the conversion price is also typical for this type of financing, providing the investor with a potential upside.
• Comparable companies often use similar convertible notes or private placements to raise capital, especially when they are not yet generating significant revenue.
• The terms are similar to other small cap biotech companies such as those listed on the OTC markets.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may be impacted by the company's financial stability and ability to continue operations.
• Creditors may be impacted by the company's ability to meet its financial obligations.
• Suppliers may be impacted by the company's ability to pay for goods and services.

Next Steps

• The company will make five scheduled payments to the investor between December 2024 and April 2025.
• The company will need to manage its cash flow to meet the payment obligations.
• The company will need to monitor its stock price and trading volume to manage the potential conversion of the note.
• The company will need to ensure compliance with all covenants and reporting requirements to avoid default.

Key Dates

Keywords

convertible promissory note, financing, biopharma, investment, debt, common stock, conversion, default, securities purchase agreement, working capital